IR@PKUHSC  > 北京大学第二临床医学院  > 眼科
学科主题临床医学
Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone for Therapy-Resistant Exudative Age-Related Macular Degeneration
Tao, Yong1,2; Jonas, Jost B.1
刊名JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
2010-04-01
DOI10.1089/jop.2009.0131
26期:2页:207-211
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Ophthalmology ; Pharmacology & Pharmacy
资助者German Academic Exchange Service (DAAD) ; German Academic Exchange Service (DAAD)
研究领域[WOS]Ophthalmology ; Pharmacology & Pharmacy
关键词[WOS]ENDOTHELIAL GROWTH-FACTOR ; VERTEPORFIN PHOTODYNAMIC THERAPY ; SUBFOVEAL FIBROVASCULAR MEMBRANES ; CHOROIDAL NEOVASCULARIZATION ; COMBINATION THERAPY ; RANIBIZUMAB ; ACETONIDE ; INJECTION ; PREVALENCE ; MACULOPATHY
英文摘要

Purpose: To investigate the effect of intravitreal bevacizumab (IVB) combined with intravitreal high-dose triamcinolone acetonide (IVTA) for therapy of exudative age-related macular degeneration (AMD) after unsuccessful IVB monotherapy.

Methods: The prospective study included 29 White patients (31 eyes) who consecutively received IVB (1.5 mg) plus high-dose IVTA (20-25 mg) for exudative AMD, after they had received multiple IVB mono-injections without functional and anatomical success. Two additional IVB injections were given in intervals of 2 months after the combined injection. The main outcome parameters were best-corrected visual acuity (BCVA) and data measured by optic coherence tomography (OCT).

Results: Mean BCVA (LogMAR) improved from 0.70 +/- 0.37 LogMAR at baseline to 0.59 +/- 0.38 LogMAR at 2 months after first follow-up (P = 0.004) and to 0.63 +/- 0.41 LogMAR (P = 0.04) at 4 months after baseline. It deteriorated to 0.68 +/- 0.41 at the end of the follow-up at 7 months after the combined injection, without a significant (P = 0.53) difference to the baseline visual acuity. The maximum macular thickness decreased significantly from 371 +/- 206 mu m at baseline to 322 +/- 90 mu m (P = 0.04) at the first follow-up and to 316 +/- 90 mu m (P = 0.03) at the second follow-up. It slightly increased toward the end of follow-up (333 +/- 133 mu m; P = 0.16). Intraocular pressure increased marginally significantly (P = 0.06) from 14.5 +/- 2.8 mm Hg to 15.7 +/- 3.3 mm Hg at the second follow-up.

Conclusions: Patients with exudative AMD, in whom monotherapy with IVB was unsuccessful, may experience a temporary improvement in vision and reduction in macular thickness after a combined intravitreal injection of bevacizumab and triamcinolone.

语种英语
资助者German Academic Exchange Service (DAAD) ; German Academic Exchange Service (DAAD)
WOS记录号WOS:000276990000012
Citation statistics
Cited Times:11[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57725
Collection北京大学第二临床医学院_眼科
作者单位1.Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany
2.Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China
Recommended Citation
GB/T 7714
Tao, Yong,Jonas, Jost B.. Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone for Therapy-Resistant Exudative Age-Related Macular Degeneration[J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS,2010,26(2):207-211.
APA Tao, Yong,&Jonas, Jost B..(2010).Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone for Therapy-Resistant Exudative Age-Related Macular Degeneration.JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS,26(2),207-211.
MLA Tao, Yong,et al."Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone for Therapy-Resistant Exudative Age-Related Macular Degeneration".JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 26.2(2010):207-211.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Tao, Yong]'s Articles
[Jonas, Jost B.]'s Articles
百度学术
百度学术Similar articles in
[Tao, Yong]'s Articles
[Jonas, Jost B.]'s Articles
必应学术
必应学术Similar articles in
[Tao, Yong]'s Articles
[Jonas, Jost B.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.